DOXYCYCLINE: LABORATORY AND CLINICAL EVALUATION
1969 Volume 17 Issue 2 Pages 197-200
Details
1969 Volume 17 Issue 2 Pages 197-200
Doxycycline (DOTC), a new derivative of tetracycline (TC), was tested against 50 strains of Staphylococcus aureus (coagulase positive) and was found to be more effective than TC.
Nineteen strains of TC resistant organisms (MIC ≥100 mcg/ml) were suppressed by less than 12. 5-. ' 25 mcg/m1 of DOTC. Five strains were inhibited between 0. 4 and 0. 8 mcg/ml.
DOTC also exhibited greater in vitro activity than TC against 50 strains of E. coli isolated from the patients.
DO TC produced and sustained higher serum levels after oral administration of 100 mg than TC. This appeared adequate for treatment of most infections due to susceptible microorganisms.
DOTC was administered 100-200 mg daily for 6-20 days orally to 11 pat ients.
Six patients responded clinically and / or bacteriologically to treatment: the diagnosis were 7 cases of respiratory infection including acute pneumonia, chronic bronchitis and infectious asthma, 2 cases of acute cholecystitis and 2 cases of pyelonephritis in acute and chronic phase.
Response of 2 cases were unsatisfactory.
DOTC was well tolerated. No side effect was seen.
It was concluded that DOTC has the advantag e as improved TC of once-daily administration, which is therapeutically effective.
